{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.51","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Time to first response is defined as the time from the initiation of therapy to the first evidence of a confirmed response (ie, CR, VGPR, PR, or MR).","dispersionType":"Standard Deviation","groups":[{"description":"Bendamustine in escalating doses of 50, 70 or 90 mg/m\\^2 as combination therapy with bortezomib at 1.0 mg/m\\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.","id":"OG000","title":"Bendamustine and Bortezomib - Overall"}],"paramType":"MEAN","populationDescription":"Participants who had a response","reportingStatus":"POSTED","timeFrame":"up to 8.5 months","title":"Time to the First Response","type":"SECONDARY","unitOfMeasure":"months"}